Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses.

Bo WangBingkun ZhouJunyu ChenXi SunWenjuan YangTenghao YangHao YuPeng ChenKe ChenXiaodong HuangXinxiang FanWang HeJian HuangTianxin Lin

Published in: Journal for immunotherapy of cancer (2024)

Our study indicated that IFN-λ3 enables macrophage-mediated phagocytosis and antitumor immune responses and suggests a rationale for using Type III IFN as a predictive biomarker and potential immunotherapeutic candidate for bladder cancer.

Keyphrases

type iii
immune response
dendritic cells
adipose tissue
toll like receptor
risk assessment
muscle invasive bladder cancer